What caused Soleno's Q2 2024 profit drop?

Soleno Therapeutics experienced a net income drop of approximately $13.37 million from Q2 2023 to Q2 2024, with a net income of -$21.85 million in Q2 2024 compared to -$8.48 million in Q2 2023. The significant decrease in net income in Q2 2024 can be attributed to several factors:

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|SLNO|SLNO.O|Soleno Therapeutics|2023 Q3|-77.12002609262883|-1.0861E7|186|
|SLNO|SLNO.O|Soleno Therapeutics|2023 Q4|-105.9059423988334|-1.1296E7|186|
|SLNO|SLNO.O|Soleno Therapeutics|2024 Q1|-156.0794638583054|-2.1398E7|186|
|SLNO|SLNO.O|Soleno Therapeutics|2024 Q2|-157.86430678466076|-2.1854E7|186|

1. **Increased Research and Development Expenses**: Soleno reported a net loss of approximately $175.9 million for the year ending December 31, 2024, which was driven by increased research and development expenses and general administrative costs. This suggests that the company may have incurred higher expenses related to drug development and clinical trials during Q2 2024.
2. **Preparations for Commercial Launch**: Soleno has been preparing for the anticipated U.S. launch of DCCR (Vykat XR), which required strengthening its commercial and medical affairs teams and making strategic investments in key programs. These preparations may have involved significant costs in Q2 2024.

In conclusion, the net income drop of Soleno Therapeutics in Q2 2024 can be attributed to increased research and development expenses and preparations for the commercial launch of DCCR.